A trial of gemfibrozil treatment was undertaken on 11 previously untreated hyperlipidcemic patients. Three further hyperlipidcmic patients who had been on clofibrate therapy were also included in the trial. Initially, one or more blood samples were taken for lipid measurements before any drug therapy, or alternatively, four or more weeks after cessation of previous lipid-lowering drugs. Subsequently, blood was taken after six weeks on placebo and then at monthly intervals during treatment with gemfibrozil, 1200 mg daily.
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In this continuing study, 11 patients have now been treated for four to 14 weeks on the active drug. A reintroduction of placebo is planned after 26 weeks on active drug therapy. Of the 11 patients, 6 showed the WHO classification type Ila lipoprotein pattern (hypercholesterolemia) before treatment. One of them had familial hypercholesterolhmia. The remaining 5 patients showed the type IV lipoprotein pattern (endogenous hypertriglyceridcemia) before treatment.
Two of the 11 patients were withdrawn from the trial, 1 after four weeks because of anorexia and vomiting. This recurred when the drug was reinstituted even at a dose of only 400 mg daily. The other patient was withdrawn after 17 weeks of treatment because of a painful swollen metacarpophalangeal joint. In her case the uric acid ana CPK measurements were normal, and we did not feel that the joint pain was a drug side effect. Other routine biochemical and hematological parameters were normal.
The serum lipoproteins were analysed as previously described (Ononogbu & Lewis 1976) . Very low density lipoprotein (VLDL) was precipitated from serum using sodium dodecylsulphate. The supernatant containing low density lipoprotein (LDL) and high density lipoprotein (HDL) was analysed, as was the precipitated VLDL (after washing and resolubilization). Using dextran sulphate, the VLDL and LDL were precipitated from a further serum sample and the resulting HDL solution was analysed. Serum VLDL and HDL could thus be measured Dr E D Janus directly, and LDL calculated by a difference method.
The sera and lipoproteins were extracted using isopropanol zeolite and the cholesterol and triglyceride concentrations were estimated by standard automated procedures (Technicon N-24a, and the method of Cramp & Robertson 1968 ). As shown in previous studies by Ononogbu & Lewis (1976) in our laboratory, the correlation between lipoprotein cholesterol and triglyceride composition using the precipitation method outlined and using preparative ultracentrifugation is excellent, with r values ranging from 0.83 for HDL triglyceride to 0.99 for VLDL triglyceride and LDL cholesterol. Table 1 shows the cholesterol and triglyceride values and lipoproteins before and during gemfibrozil treatment. In the 5 patients (Patients 7-11) with endogenous hypertriglyceridemia, serum cholesterol was reduced in 3 and triglyceride in 4, the triglyceride being reduced to a greater extent (mean 36%) than the cholesterol (mean 13 %). The fall in serum triglyceride was due chiefly to a fall in VLDL triglyceride (mean 45%), but falls in VLDL cholesterol were also found (mean 32 %). LDL cholesterol changed little, but there was a reduction of LDL triglyceride in some cases. In HDL the most striking change was an increase in the HDL cholesterol by about 31 %.
Four of the 6 patients with hypercholesterolmmia (Patients 1-6) showed a reduction of serum cholesterol (mean 17 %), and 3 showed a lowering of serum triglycerides (mean 30%). When they occurred, the reductions in serum cholesterol and triglyceride seemed to be due mainly to a lowering of VLDL cholesterol (37 %) and triglyceride Table 1 Cholesterol and triglyceride values for srum and lipoprotensm before (I) and during (II) gemfibrozil treatment.
Patients 1-6 had hypercholesterolamia and Patients 7-11 had endogenous hypertriglycerid2emia Serum  Serum  VLDL  VLDL  LDL  LDL  HDL  HDL   cholesterol triglyceride cholesterol triglyceride cholesterol triglyceride cholesterol triglyceride   Patient  No.  I  II  I  I  II  I  1  I  II  I  II  I  II  I  II   1 6.5 6.7 4.60 6.72 -- 
Summary
During treatment with gemfibrozil, 1200 mg daily, total serum triglyceride levels were reduced in 7 of the 11 patients, owing chiefly to a fall in VLDL triglyceride levels.
Total serum cholesterol responded variably, falling in a majority of patients with hypercholesterolkemia.
High density lipoprotein cholesterol rose during treatment in patients who had either hypertriglyceridemia or hypercholesterolkmia.
